Ivan Inigo

2.4k total citations
21 papers, 693 citations indexed

About

Ivan Inigo is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Ivan Inigo has authored 21 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Ivan Inigo's work include Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and HER2/EGFR in Cancer Research (5 papers). Ivan Inigo is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and HER2/EGFR in Cancer Research (5 papers). Ivan Inigo collaborates with scholars based in United States, Germany and United Kingdom. Ivan Inigo's co-authors include Stephen Castaneda, David Kan, Christine Flefleh, Amy Camuso, Kelly McGlinchey, Krista Fager, Robert A. Kramer, Gerald E. Hall, David Schaer and Michael Kalos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Ivan Inigo

21 papers receiving 680 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ivan Inigo United States	10	363	225	160	146	112	21	693
Stephen Castaneda United States	10	356 1.0×	217 1.0×	146 0.9×	134 0.9×	96 0.9×	14	685
Jamie L. DellaGatta United States	6	299 0.8×	273 1.2×	293 1.8×	81 0.6×	90 0.8×	8	658
Richard Smykla United States	11	279 0.8×	202 0.9×	68 0.4×	224 1.5×	165 1.5×	16	637
Glenn Michelson United States	14	282 0.8×	340 1.5×	112 0.7×	146 1.0×	83 0.7×	51	668
Ruth Seggewiss‐Bernhardt Germany	12	409 1.1×	434 1.9×	214 1.3×	87 0.6×	152 1.4×	19	889
Konrad Aumann Germany	16	220 0.6×	346 1.5×	134 0.8×	163 1.1×	155 1.4×	41	731
Paul A. Algate United States	7	146 0.4×	269 1.2×	100 0.6×	68 0.5×	58 0.5×	12	528
Sophie Derenne France	8	362 1.0×	418 1.9×	159 1.0×	338 2.3×	59 0.5×	11	780
Yvette van Hensbergen Netherlands	12	348 1.0×	301 1.3×	129 0.8×	132 0.9×	55 0.5×	22	666
Yves Toiron France	13	236 0.7×	423 1.9×	112 0.7×	251 1.7×	135 1.2×	21	823

Countries citing papers authored by Ivan Inigo

Since Specialization

Citations

This map shows the geographic impact of Ivan Inigo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Inigo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Inigo more than expected).

Fields of papers citing papers by Ivan Inigo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Inigo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Inigo. The network helps show where Ivan Inigo may publish in the future.

Co-authorship network of co-authors of Ivan Inigo

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Inigo. A scholar is included among the top collaborators of Ivan Inigo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Inigo. Ivan Inigo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGrath, Lara, Ying Zheng, Sihem Khelifa, et al.. (2023). Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate. Cancer Research. 83(7_Supplement). 5737–5737. 9 indexed citations

Li, Yanxia, Nelusha Amaladas, Jason R. Manro, et al.. (2022). Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. PLoS ONE. 17(7). e0268244–e0268244. 11 indexed citations

Alonso, Marta M., Ivan Inigo, Marisol González-Huarriz, et al.. (2019). OS5.1 Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs. Neuro-Oncology. 21(Supplement_3). iii11–iii11. 1 indexed citations

Holmgaard, Rikke, David Schaer, Yanxia Li, et al.. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for ImmunoTherapy of Cancer. 6(1). 47–47. 267 indexed citations

Schaer, David, Yanxia Li, Stephen Castaneda, et al.. (2016). Abstract A091: Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Cancer Immunology Research. 4(1_Supplement). A091–A091. 1 indexed citations

Schaer, David, Yanxia Li, Stephen Castaneda, et al.. (2015). Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P402–P402. 1 indexed citations

Wang, Lin, Hui Feng, Kristen Lekstrom, et al.. (2013). Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis. Molecular Cancer Therapeutics. 12(7). 1235–1244. 43 indexed citations

Leow, Ching Ching, Ivan Inigo, Suneetha B. Thomas, et al.. (2013). Abstract A49: Anti-DLL4 antibodies inhibit cancer stem cells in small cell lung cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). A49–A49. 1 indexed citations

Chen, Hong, Ivan Inigo, Rosa A. Carrasco, et al.. (2012). Abstract 239: A novel multimeric protein scaffold stimulates apoptotic signaling through TRAILR2. Cancer Research. 72(8_Supplement). 239–239. 1 indexed citations

10.

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2006). Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure. Clinical Cancer Research. 12(23). 7180–7186. 113 indexed citations

11.

Wild, Robert A., Krista Fager, Christine Flefleh, et al.. (2006). Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Molecular Cancer Therapeutics. 5(1). 104–113. 60 indexed citations

12.

Lee, Francis Y., Louis J. Lombardo, Amy Camuso, et al.. (2005). BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Cancer Research. 65. 159–159. 38 indexed citations

13.

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2005). Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemotherapy and Pharmacology. 56(5). 455–464. 66 indexed citations

14.

Luo, Feng, Zheng Yang, Huijin Dong, et al.. (2005). Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model. Clinical Cancer Research. 11(15). 5558–5565. 22 indexed citations

15.

Lee, Francis Y., Mei-Li Wen, Rajeev S. Bhide, et al.. (2005). Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).. Blood. 106(11). 1994–1994. 14 indexed citations

16.

Lee, Francis Y., Mei-Li Wen, Amy Camuso, et al.. (2005). Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.. Blood. 106(11). 1993–1993. 5 indexed citations

17.

Castaneda, Stephen, Ivan Inigo, David Kan, et al.. (2005). Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. Journal of Clinical Oncology. 23(16_suppl). 561–561. 26 indexed citations

18.

Lee, Francis Y., Louis J. Lombardo, R. M. Borzilleri, et al.. (2004). Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Cancer Research. 64. 921–921. 3 indexed citations

19.

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2004). Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.. Blood. 104(11). 1987–1987. 1 indexed citations

20.

Wild, Robert A., Stephen Castaneda, Christine Flefleh, et al.. (2004). BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.. Blood. 104(11). 1988–1988. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact